CorMedix reports $54.5 million in Q3 revenue and raises EBITDA guidance
CorMedix reported third-quarter 2026 revenue of $54.5 million and narrowed full-year adjusted EBITDA guidance to $130 million–$140 million.
CorMedix reported third-quarter 2026 revenue of $54.5 million and narrowed full-year adjusted EBITDA guidance to $130 million—$140 million.Key Highlights:Original SEC Filing: CorMedix Inc. [ CRMD ] - 8-K - Nov. 13, 2026This is an AI-powered summary. It may contain inaccuracies.
Consider verifying i…